News

The accelerated approval is based on phase 3 data demonstrating seladelpar’s impact on ALP reduction and is contingent upon verification and description of clinical benefit in confirmatory trial(s).

These data show that izokibep treatment of HS met each of its key primary and key secondary endpoints.

A ranibizumab biosimilar lowers costs compared with aflibercept across all nAMD subtypes from both the patient and societal perspectives.

This analysis was conducted to evaluate the effect of pruritus on quality of life ratings among individuals with atopic dermatitis and psoriasis.

Deepak Bhatt, MD, MPH, MBA, discusses 7 trials to watch from hotline or late-breaking sessions at the upcoming European Society of Cardiology Congress 2024.

Noureddin explains the discordance between FIB-4 and transient elastography for stratifying fibrosis risk and emphasizes the importance of repetition and attentiveness with FIB-4.

Preliminary Phase 1b data demonstrated the favorable safety and tolerability profile of VLS-01 buccal film, with psychedelic effects resolved by 120 minutes.

In this analysis, the biggest predictors of biologic initiation among individuals with diagnoses of psoriasis were evaluated.

Findings suggest increased intensity of IgM deposits in patients with positive IgM deposition may contribute to adverse clinicopathologic presentation and clinical outcomes.

Announced by Rivus Pharmaceuticals, HU6 met its primary endpoint of weight reduction in patients with obesity-related HFpEF in a Phase 2a trial.

Adding vitrectomy with ILM peeling to a treat-and-extend anti-VEGF therapy showed no benefit on visual or anatomic outcomes in DME treatment.

The drug is the first approved monoclonal antibody specifically designed to inhibit the IL-31 pathway, a driver of prurigo nodularis.

This analysis highlights data regarding agreement between various smartphone applications used for detection of melanoma.

Laurence Sperling, MD, provides an overview of the Family Heart Global Summit, including previewing the meeting and discussing where interested attendees can learn more.

Findings highlight a 78.4% treatment success rate among patients who prematurely discontinued DAAs, reaching 93.5% among those who discontinued after week 4.

Ravulizumab therapy may enable patients with PNH to achieve activity and patient-reported outcomes comparable to the US general population.

Maintaining stable HbA1c levels in target ranges reduces Alzheimer Disease risk in older adults with diabetes, emphasizing the importance of personalized glycemic control.

In this interview, Kim speaks about the significance of the FDA approval of neffy for patients who face the threat of anaphylaxis and other severe allergic reactions.

The updated pediatric IgAN prediction tool allows clinicians to assess risk of disease progression 1-2 years post-biopsy.

Cristina Pearse, an MDMA-assisted therapy trial participant, expresses disappointment in the FDA’s decision not to approve MDMA-assisted therapy.

A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists in type 2 diabetes.

Palopegteriparatide’s approval was based on positive data from the global Phase 2 PaTH Forward and Phase 3 PaTHway trials.

This analysis compared drug survival rates of abrocitinib and dupilumab in the treatment of adults with eczema, with different benefits highlighted for both therapies.

Mora and Sadreameli join Lungcast to provide a back-to-school health blueprint, including topics like rescue inhalers, vaccination, vaping and air quality.

Alkhouri explains the value of AGILE 3+ and AGILE 4, reviewing key findings from a recent study applying the scores to NHANES data to estimate MASLD fibrosis and cirrhosis.

Projections from an agent-based model based on data from Ontario, Canada, suggest both current and prospective strategies may not meet World Health Organization HCV goals.

Thrombotic risk is more likely influenced by disease status than hormonal contraception exposure in women with SCD.

In this analysis, investigators compared deucravacitinib in terms of patient-reported outcomes versus those of placebo and apremilast.